S-1-based vs non-S-1-based化疗在晚期胃癌:一个荟萃分析。
文章的细节
-
引用
复制到剪贴板 -
杨J,周Y,分钟K,姚明问,徐CN
S-1-based vs non-S-1-based化疗在晚期胃癌:一个荟萃分析。
世界杂志。2014年9月7日,20 (33):11886 - 93。doi: 10.3748 / wjg.v20.i33.11886。
- PubMed ID
-
25206296 (在PubMed]
- 文摘
-
目的:评估的有效性和耐受性S-1-based vs non-S-1-based化疗在晚期胃癌(AGC)。方法:我们报告中提取端点,包括总生存期(OS),无进展生存(PFS), time-to-treatment失败(TTF),客观缓解率(ORR)和不利影响,从随机对照试验确定在PubMed Cochrane图书馆、科学指导、EMBASE和美国临床肿瘤学会会议。占据软件用于计算集中值。结果:七个随机对照试验在这个荟萃分析中包括2176名患者。non-S-1-based方案相比,使用S-1-based方案与增加有关奥尔(RR = 1.300;95%置信区间:1.028—-1.645);操作系统(HR = 0.89;95%置信区间:0.81—-0.99;P = 0.025), TTF (HR = 0.83;95%置信区间:0.75—-0.92; P = 0.000), and a lower risk of febrile neutropenia (RR = 0.225; P = 0.000) and stomatitis (RR = 0.230; P = 0.032). OS, PFS and TTF were prolonged, especially in the Asian population. In subgroup analysis, statistically significant increases in ORR (RR = 1.454; P = 0.029), OS (HR = 0.895; P = 0.041) and TTF (HR = 0.832; P = 0.000) were found when S-1-based chemotherapy was compared to 5-fluorouracil (5-FU)-based chemotherapy. The incidence of leukopenia (RR = 0.584; P = 0.002) and stomatitis (RR = 0.230; P = 0.032) was higher in the 5-FU-based arm. S-1-based regimens had no advantage in ORR, OS, PFS, TTF and grade 3 or 4 adverse events over capecitabine-based regimens. CONCLUSION: S-1-based chemotherapy may be a good choice for AGC because of longer survival times, better tolerance and more convenient use.
DrugBank数据引用了这篇文章
- 药物